Home » Stocks » Insulet

Insulet Corporation (PODD)

Stock Price: $202.45 USD -0.91 (-0.45%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $202.50 +0.05 (0.03%) Aug 3, 4:20 PM

Stock Price Chart

Key Info

Market Cap 13.25B
Revenue (ttm) 776.60M
Net Income (ttm) 5.12M
Shares Out 65.45M
EPS (ttm) 0.08
PE Ratio 2,530.63
Forward PE 454.55
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $202.45
Previous Close $203.36
Change ($) -0.91
Change (%) -0.45%
Day's Open 204.37
Day's Range 198.58 - 205.89
Day's Volume 460,363
52-Week Range 115.56 - 228.79

More Stats

Market Cap 13.25B
Enterprise Value 13.83B
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 65.45M
Float 62.47M
EPS (basic) 0.08
EPS (diluted) 0.08
FCF / Share -0.91
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.04%
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.86M
Short Ratio 4.98
Short % of Float 5.42%
Beta 0.90
PE Ratio 2,530.63
Forward PE 454.55
P/FCF Ratio n/a
PS Ratio 17.06
PB Ratio 225.61
Revenue 776.60M
Operating Income 50.24M
Net Income 5.12M
Free Cash Flow -56.91M
Net Cash -577.40M
Net Cash / Share -8.82
Gross Margin 61.85%
Operating Margin 6.47%
Profit Margin 0.70%
FCF Margin -7.33%
ROA 3.05%
ROE 3.61%
ROIC 2.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (21)

Buy 7
Overweight 2
Hold 11
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

$219.41*
(8.38% upside)
Low
165
Current: $202.45
High
250
Target: 219.41
*Average 12-month price target from 17 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue73856446436726423124721115296.97
Revenue Growth30.93%21.56%26.38%39.07%14.08%-6.38%16.9%38.83%57.02%-
Gross Profit48037027721113312711292.3466.7143.73
Operating Income50.0027.40-7.40-10.70-48.74-8.87-29.14-35.97-42.47-38.63
Net Income11.603.30-26.80-28.88-73.52-51.50-44.97-51.87-45.83-61.16
Shares Outstanding60.5958.8658.0057.2556.7955.6354.0147.9246.6939.61
Earnings Per Share0.190.05-0.46-0.51-1.29-0.92-0.83-1.08-0.98-1.54
EPS Growth280%---------
Operating Cash Flow98.4035.9041.3015.91-12.558.923.35-29.06-25.45-35.63
Capital Expenditures-164-157-73.80-22.12-10.61-11.49-7.31-10.99-11.11-6.55
Free Cash Flow-65.30-122-32.50-6.20-23.16-2.57-3.96-40.05-36.57-42.17
Cash & Equivalents37628944029912315115057.2993.96113
Total Debt88859256633317717012211810969.43
Net Cash / Debt-512-303-126-34.20-54.81-18.4728.05-60.87-14.5943.84
Assets1,143929817457275297288198221156
Liabilities1,06771765839324121316315413990.00
Book Value75.9021215963.1534.0583.8312544.1882.7466.23
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Insulet Corporation
Country United States
Employees 1,350
CEO Shacey Petrovic

Stock Information

Ticker Symbol PODD
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: PODD
IPO Date May 15, 2007

Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.